Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Docetaxel (Taxotere®)–cisplatin (TC): An effective drug combination in gastric carcinoma (2000)
    Springer
    Annals of oncology 11 (2000), S. 301-306 
    Details
    ISSN: 1569-8041
    Keywords: chemotherapy ; docetaxel ; gastric cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose:A multi-centric trial was performed to explore theclinical activity, in terms of response and toxicity (primary objectives),duration of response and survival (secondary objectives), of docetaxel withcisplatin in advanced gastric cancer (AGC). Patients and methods:Patients with measurable unresectable and/ormetastatic gastric carcinoma, performance status ≤1, normal hematological,hepatic and renal functions and not pretreated for advanced disease bychemotherapy received up to eight cycles of TC (docetaxel 85 mg/m2d1, cisplatin 75 mg/m2 d1) q3w. Dose escalation to 100mg/m2 was performed in five patients and was discontinued forexcessive toxicity. Results:Forty-eight patients were accrued. A median of 5cycles/patient was given. We observed 2 complete and 25 partial responses foran overall intent to treat response rate of 56% (95% CI:41%–71%). Twelve patients had stable disease for ≥9weeks (3 cycles). The median time to progression and overall survival were 6.6and 9 months, respectively. Grade ≥3 toxicities were neutropenia81%, anemia 32%, thrombocytopenia 4%, alopecia36%, fatigue 9%, mucositis 9%, diarrhea 6%,nausea/vomiting 4%, neurologic 2%, and one anaphylaxisprecluding treatment administration. We recorded nine episodes of non-fatalfebrile neutropenia in eight patients, two of them with docetaxel at 100mg/m2. There were no direct treatment-related deaths. Conclusions:TC is active in AGC with a high response rate in amulticentric trial. Despite its hematotoxicity, this regimen is well toleratedand can be recycled as originally planned in 78% of the cases. Theseresults may serve as basis for further developments of docetaxel containingregimens in this disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008342013224
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Parathyroid hormone-related protein in metastatic breast cancer induced hypercalcemia: A case report (2000)
    Springer
    Annals of oncology 11 (2000), S. 97-100 
    Details
    ISSN: 1569-8041
    Keywords: bisphosphonates ; malignant hypercalcemia ; metastatic breast cancer ; paraneoplastic syndrome ; parathyroid hormone-related protein
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008319323222
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Proposing phase I studies: Patients', relatives', nurses' and specialists' perceptions (2000)
    Springer
    Annals of oncology 11 (2000), S. 289-294 
    Details
    ISSN: 1569-8041
    Keywords: informed consent ; phase I studies
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose:As of now the primary objective of studies on informedconsent in phase I trials has been to assess patients' expectations andreasons for participation. We have previously shown that the quantity ofinformation provided through a procedure of subsequent oral interviews withpatients was adequate while the attention paid by the physician to theemotional needs and concerns of patients was not. We wanted therefore toassess and compare the perceptions of the information provided about theinvestigational study of patients, relatives, the research nurse and theinvestigator responsible for the phase I trial and the impact this informationhad on the patients' level of anxiety and depression. Patients and methods:The participation to a phase I study wasproposed to patients through two subsequent interviews, the latter attendedalso by patients' relatives, the research nurse and the investigatorcoordinating the phase I trial. After the second interview, attendees wererequested to complete a questionnaire assessing the principal reason forparticipating in the study and the informative, emotional and interactivedimension of the information. Patients were also requested to complete theHospital Anxiety and Depression (HAD) scale before and after the secondinterview. Results:The completed questionnaires of 31 of 42 patients wereretrieved and analysed. The possibility to benefit from the study wasindicated as the main reason for participating by 59% of the patientswhile it was judged to be the case in 78% and 86% of thepatients by the nurse and the investigator, respectively. The information wasjudged to be clear and sufficient in almost all cases by all attendees, whilethe investigator judged that a lower percentage of patients felt at ease andcould express their main worries during the interview, had been helped andwere less worried after it than it was judged by the nurse and the relatives.Patients' state of anxiety and depression was not adversely affected by theinformation provided. Conclusions:Informing patients on the option of receiving aninvestigational treatment within a phase I study is feasible and can be donein a way felt appropriate by patients and relatives, nursing and medicalprofessionals. Providing information in an appropriate manner does notincrease patients' anxiety and depression. Divergence between the aims andinterests of the investigators and patients might explain the difference inthe evaluation of physician, a problem which could perhaps be partiallyovercome by the application of innovative phase I designs.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008393031299
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study (2000)
    Springer
    Annals of oncology 11 (2000), S. 985-991 
    Details
    ISSN: 1569-8041
    Keywords: advanced breast cancer ; docetaxel ; epidoxorubicin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background:The combination of anthracyclines and taxanes iscurrently considered the first choice chemotherapy in advanced breast cancer(ABC) and considerable emphasis has been placed on programs exploring thesafest and most efficient way to integrate these classes of drugs in both themetastatic and, more recently, the adjuvant setting. We report here the overall results of the combination of epidoxorubicin (E)90 mg/m2 and docetaxel (D) 75 mg/m2 as first-linechemotherapy in ABC. Patients and methods:A total of 70 patients were entered in theinitial dose-finding study (20 patients) and in the subsequent extended phaseII trial (50 patients). Overall 54% of patients had dominant visceraldisease and 57% had at least two metastatic sites. Adjuvantanthracyclines were allowed in the phase II part of the study based on thelack of cardiac toxicity observed in the phase I study at a median cumulativeE dose of 480 mg/m2. A maximum of eight cycles of the combinationwas allowed, and cardiac function was monitored at baseline and after everysecond course by echocardiography. Results:Overall, the median number of cycles administered withthe combination was 4 (range 3–8). Neutropenia was confirmed to be themain haematological toxicity, with granulocyte colony-stimulating factor(G-CSF) support required in 44% of the cycles. Febrile neutropeniaoccurred in 12% of cycles of the combination but 52% of theepisodes could be managed on an outpatient basis with oral antibiotics.Overall, the median cumulative dose of E, including prior adjuvantanthracyclines, was 495 mg/m2 (range 270–1020mg/m2). One patient who received adjuvant E together withradiotherapy to the left chest wall developed fully reversible clinical signsof cardiotoxicity and a significant decrease of LVEF to 35% after acumulative E dose of 870 mg/m2, with four additional patients(6%) developing asymptomatic and transient decline of resting LVEF. Theoverall response rate (ORR) in 68 evaluable patients was 66%(95% confidence interval (95% CI): 54%–73%).A comparable antitumour activity of 71% was reported in the group ofpatients with a prior adjuvant chemotherapy with anthracyclines. After anoverall median follow-up time of 22 months (range 4–39+), the mediantime to progression (TTP) was 4.5 months and the median duration of responsewas 8 months (range 3–16). No pharmacokinetic (Pk) interaction could bedemonstrated between E and D when given simultaneously and sequentially witha one-hour interval. Conclusions:The combination of E and D in a multi-institutionalsetting is an active and safe regimen in poor- prognosis patients with ABC.New combinations and schedules are worth considering in an attempt to furtherimprove disease response and long-term control of the disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008392927656
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...